What physical examination items need to be done while using Vigabatrin/vigabatrin

During the treatment of epilepsy with Vigabatrin/vigabatrin, in order to ensure the safety and sustainability of the drug, clinicians usually recommend that patients cooperate with regular physical examination monitoring, especially those closely related to the risk of adverse reactions unique to the drug. The main metabolic mechanism of vigabatrin does not rely on the liver enzyme system, but its long-term use is associated with retinal toxicity, so monitoring of vision has become one of the core physical examination items.

Ophthalmic examinations are an essential monitoring measure during treatment with vigabatrin. This drug may cause irreversible peripheral visual field defect (PRVF), and some patients have no symptoms in the early stages. During the initial period of use, it is recommended that patients undergo a baseline visual field examination before taking the drug, and then re-examine every three to six months, using an automated perimeter (such as a Humphrey perimeter) for evaluation. For pediatric patients or those unable to cooperate with the visual field test, electroretinography (ERG) or OCT can be used instead to observe changes in retinal function or structure.

In addition to ophthalmology items, renal function testing is also one of the recommended items, because vigabatrin is mainly excreted through the kidneys. In patients with renal insufficiency, the drug may accumulate, increasing the risk of side effects, so creatinine levels and eGFR estimates should be checked regularly to adjust dosage. For infants and young children, it is recommended to increase monitoring of weight, head circumference development and neurobehavioral evaluation to rule out the potential risk of drugs affecting development.

In addition, some patients may experience central nervous system adverse reactions such as depression and behavioral changes during long-term use. Therefore, regular clinical assessment of mental status is also recommended. In certain populations (such as those taking other medications), blood drug concentrations also need to be monitored to assess the possibility of drug interactions.

Reference materials:https://www.sabril.net/